Palvella Therapeutics
PVLA
33 hedge funds and large institutions have $48.4M invested in Palvella Therapeutics in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
380% more capital invested
Capital invested by funds: $10.1M → $48.4M (+$38.3M)
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
32% more funds holding
Funds holding: 25 → 33 (+8)
9.93% less ownership
Funds ownership: 45.88% → 35.95% (-9.9%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$11.2M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$10.7M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$10M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$6.89M |
| 5 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$6.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$621K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
-$373K |
| 3 |
Renaissance Technologies
New York
|
-$170K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$23K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20.1K |
PVLA Hedge Fund Activity: Q4 2024 in Review
33 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2024, worth a combined $48.4M — up 380% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PVLA positions and 3 closed out — a net gain of 8 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $11.2M. The largest seller was Lynx1 Capital Management, exiting entirely with an estimated $621K sold.
- 33 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2024, up from 25 in Q3 2024.
- Funds reported $48.4M of Palvella Therapeutics stock for Q4 2024, up 380% quarter-over-quarter.
- 11 funds opened new Palvella Therapeutics positions in Q4 2024 and 3 closed out, a net change of +8 holders.
- The largest Palvella Therapeutics buyer in Q4 2024 was Suvretta Capital Management, an estimated $11.2M added.
- The largest Palvella Therapeutics seller in Q4 2024 was Lynx1 Capital Management, an estimated $621K sold.
Based on aggregated 13F filings for Q4 2024.